Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Cenobamate

  • Home
  • Cenobamate
Superior Efficacy of Cenobamate in Drug-Resistant Focal Epilepsy: Real-World Evidence
Posted inNeurology news

Superior Efficacy of Cenobamate in Drug-Resistant Focal Epilepsy: Real-World Evidence

Posted by MedXY By MedXY 04/29/2026
This article reviews a large real-world study demonstrating cenobamate's superior effectiveness over brivaracetam, lacosamide, and perampanel in reducing seizures for adults with drug-resistant focal epilepsy.
Read More
Cenobamate Outperforms Brivaracetam, Lacosamide, and Perampanel in Real-World Focal Epilepsy Management
Posted inNeurology news

Cenobamate Outperforms Brivaracetam, Lacosamide, and Perampanel in Real-World Focal Epilepsy Management

Posted by MedXY By MedXY 02/10/2026
A large multicenter real-world study indicates that cenobamate provides superior effectiveness and seizure freedom rates compared to brivaracetam, lacosamide, and perampanel in adults with drug-resistant focal epilepsy, despite a higher incidence of adverse effects.
Read More
  • Impact of Ring Pessary on Pelvic Anatomy in Upright Position: Insights from Prospective Upright MRI Study
  • Unveiling Posttraumatic Stress Trajectories Following Vaginal Delivery: Implications for Early Identification and Intervention
  • Optimizing Postpartum Care: Evaluating High-Dose Oxytocin Infusion to Reduce Blood Loss After Vaginal Delivery
  • Strategic Sequencing of Systemic Therapies in Advanced Hepatocellular Carcinoma: Beyond the Second Line
  • Functional Anti-preS1 Antibody Responses and Their Role in Viral Control in Chronic Hepatitis B
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in